Marta Santisteban Eslava-rekin lankidetzan egindako argitalpenak (9)

2018

  1. Erratum: Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial (Brachytherapy (2018) 17(5) (734–741), (S1538472118300898) (10.1016/j.brachy.2018.04.007))

    Brachytherapy

  2. Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial

    Brachytherapy, Vol. 17, Núm. 5, pp. 734-741

2016

  1. Multicatheter breast implant during breast conservative surgery: Novel approach to deliver accelerated partial breast irradiation

    Brachytherapy, Vol. 15, Núm. 4, pp. 485-494

2015

  1. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis

    Journal of Translational Medicine, Vol. 13, Núm. 1

  2. Safety and efficacy of temsirolimus under compassionate use in heavily pretreated patients with poor-prognosis solid tumors

    Minerva Chirurgica

  3. Time to loading and locoregional control in perioperative high-dose-rate brachytherapy: The tumor bed effect revisited

    Brachytherapy, Vol. 14, Núm. 4, pp. 565-570

2014

  1. Epidermal growth factor receptor targeting in non-small cell lung cancer: Revisiting different strategies against the same target

    Current Drug Targets, Vol. 15, Núm. 14, pp. 1273-1283

  2. Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed

    Journal of Translational Medicine, Vol. 12, Núm. 1

2013

  1. Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: A retrospective cohort study

    Journal of Neuro-Oncology